Peer-reviewedLicence not statedGastroenterology
Potential for GLP-1 Receptor Agonists in Irritable Bowel Syndrome
- 1Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
- 2Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds, UK
- 3Leeds Gastroenterology Institute, St James’s University Hospital, Leeds, UK
Related
- Irritable bowel syndrome and restless legs syndrome: a narrative review of epidemiological and pathophysiological overlap
- Gut microbial functional associations with subsequent irritable bowel syndrome in a prospective, paediatric case–control study
- Circulating Zonulin in Irritable Bowel Syndrome: A Systematic Review of Conflicting Evidence and the Critical Impact of Assay Specificity
- Clinical, functional, and quality-of-life characteristics of women with comorbid fibromyalgia and irritable bowel syndrome and their associations with FIQR scores
- Enteroendocrine signaling in irritable bowel syndrome: beyond cell counts toward stimulus-responsive physiological profiling
BibTeX
@article{camilleri2026potential,
title = {{Potential for GLP-1 Receptor Agonists in Irritable Bowel Syndrome}},
author = {Michael Camilleri and Alexander C. Ford},
journal = {Gastroenterology},
year = {2026},
month = oct,
doi = {10.1053/j.gastro.2026.10.378},
url = {https://doi.org/10.1053/j.gastro.2026.10.378},
}
RIS
TY - JOUR
TI - Potential for GLP-1 Receptor Agonists in Irritable Bowel Syndrome
AU - Michael Camilleri
AU - Alexander C. Ford
PY - 2026
DA - 2026/10/23
JO - Gastroenterology
DO - 10.1053/j.gastro.2026.10.378
UR - https://doi.org/10.1053/j.gastro.2026.10.378
SN - 0016-5085
SN - 1528-0012
ER -